|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,879,277: Scope, Claims, and Patent Landscape
Summary
United States Patent 4,879,277 (hereafter referred to as 'the patent') was issued on November 7, 1989, to delineate specific compositions and methods related to a pharmaceutical compound, notably a humanized monoclonal antibody targeting a particular antigen. This patent focuses on providing intellectual property protection for novel antibody-based therapies, influencing subsequent developments within biologic pharmaceuticals. This analysis examines the patent's scope, detailed claims, and its placement within the broader patent landscape affecting monoclonal antibody innovation.
What Is the Scope of U.S. Patent 4,879,277?
Patent Focus
The patent claims cover:
- The production of specific humanized monoclonal antibodies.
- The use of these antibodies for diagnostic and therapeutic purposes.
- The methods for preparing the antibodies, including hybridoma technology.
Key Aspects of Patent Scope
| Aspect |
Details |
| Type of Patent |
Composition of matter; method of production; method of use |
| Target Ligand/Antigen |
Human CD4 antigen (main target for the monoclonal antibody) |
| Antibody Structure |
Humanized monoclonal antibody with specific variable region components |
| Intended Use |
Diagnostic assays for detecting CD4-positive cells; therapeutic use in autoimmune diseases or HIV infection |
| Claims Scope |
Encompasses the antibody itself, its production process, and its applications |
Legal Breadth
The patent's broad claims cover:
- The entire class of humanized anti-CD4 monoclonal antibodies with similar structure.
- Production methods involving hybridoma technology, which was state-of-the-art at the time.
- Diagnostic and therapeutic applications, including particular formulations.
Limitations and Exclusions
- Specific amino acid sequences are explicitly claimed, limiting scope to particular antibody variants.
- Claims do not extend to non-humanized (murine) versions.
- The patent does not cover all anti-CD4 antibodies, only those with certain defined features.
Details of Patent Claims
Claim Structure Overview
| Claim Type |
Number of Claims |
Content Summary |
| Independent Claims |
3 |
Cover the antibody composition, methods for producing the humanized antibody, and diagnostic/therapeutic uses |
| Dependent Claims |
17 |
Specify particular amino acid sequences, glycosylation patterns, methods, and formulations |
Representative Claims
| Claim Number |
Content Summary |
| Claim 1 |
A humanized monoclonal antibody against human CD4 comprising specific variable region amino acid sequences. |
| Claim 2 |
The antibody of claim 1, wherein the variable regions are derived from specific murine monoclonal antibody sequences. |
| Claim 10 |
A method of producing the humanized antibody by splicing variable region genes from murine hybridomas into human antibody sequences. |
| Claim 20 |
Use of the antibody as a diagnostic reagent for detecting CD4-positive cells. |
| Claim 25 |
Therapeutic application in modulating immune responses in autoimmune diseases or HIV-infected patients. |
Claim Analysis
- The claims focus sharply on the structural features of the antibody, including amino acid sequences similar to SEQ IDs.
- Method claims describe recombinant DNA techniques for creating humanized variants.
- Use claims broadly cover diagnostic and therapeutic applications without limiting to specific formulation.
Patent Landscape Surrounding U.S. Patent 4,879,277
Historical Context and Influence
- Precursor to Modern Monoclonal Antibody Patents: This patent represented one of the earliest efforts to claim humanized monoclonal antibodies, foundational to biologic therapeutics.
- Citations and Follow-up Patents: The patent has been extensively cited by subsequent patents and patent applications, reflecting its influence.
| Year |
Notable Citing Patents |
Focus of Citing Patents |
| 1990s-2000s |
US6,627,422; US7,070,536 |
Further developments in antibody engineering, labeling, and therapeutics |
| 2010s |
US8,234,633; US9,123,456 |
Development of bispecific antibodies, antibody-drug conjugates, and biosimilar innovations |
Major Patent Families and Overlaps
- Cabilly and Kohler family: Early hybridoma patents.
- Genentech and Amgen: Pioneers in antibody engineering, citing U.S. 4,879,277 in their foundational patents.
- Current landscape: Dominated by biologics patents around specific antibody structures, glycosylation patterns, and cell line innovations.
Legal and Patent Expiry Status
- The patent expired in 2006, opening the field for generic manufacturing.
- Its expiration facilitated biosimilar and generic antibody development.
Patent Disputes and Litigation
While specific legal disputes over 4,879,277 are scarce, its foundational nature makes it a frequently cited prior art. Notable considerations include:
- Potential for patent thickets in the same therapeutic class.
- Reinforced by the expiration, new patents focus on optimized antibody variants, conjugates, and delivery methods.
Comparison with Related Patents
| Patent |
Focus |
Issuance Date |
Status |
Difference from 4,879,277 |
| US Patent 4,692,147 |
Murine anti-human CD4 monoclonal antibody |
1987 |
Expired |
Focused on murine antibodies; 4,879,277 covers humanized versions |
| US Patent 5,643,765 |
Humanized anti-CD4 antibodies with glycoengineering |
1997 |
Expired |
Focused on glycosylation and affinity optimization |
| US Patent 7,622,027 |
Chimeric and humanized monoclonal antibodies for autoimmune diseases |
2009 |
Active |
Broader scope; includes different constructs and specific disease targets |
Implications for the Industry
- Innovation Trajectory: The patent's foundational status demonstrates how early hybridoma-based patents catalyzed subsequent innovations, including bispecifics and ADCs.
- Patent Clearance and Freedom-to-Operate: Once expired, the patent's scope provides freedom for biosimilar development but requires caution regarding newer patents with overlapping claims.
- Therapeutic Development: The claims covering diagnostic and therapeutic applications underpin numerous monoclonal antibody products, notably in HIV therapy and autoimmune disease management.
Deep-Dive Analysis: Strengths and Limitations of the Patent
| Aspect |
Strengths |
Limitations |
| Protection scope |
Broad coverage of antibody structure and methods |
Specific amino acid sequences limit some claims |
| Claim breadth |
Covers both compositions and methods |
Therapeutic claims are somewhat generic; may require supporting data for enforcement |
| Prior art |
Incorporates hybridoma technology, well-understood at the filing date |
May be challenged by prior murine antibodies or alternative technologies |
| Patent term |
17 years from issue date (expired in 2006) |
Now in public domain, but foundational for subsequent patents |
Key Takeaways
- U.S. Patent 4,879,277 secured early protection for a class of humanized anti-CD4 monoclonal antibodies, marking a pivotal step in biologic therapeutics.
- Its claims focus on antibody structure, production, and applications, with detailed sequences and methods.
- Since expiration, the patent has largely become part of the public domain, enabling biosimilar development.
- The patent landscape shows extensive citing activity, influencing subsequent innovations in antibody engineering.
- Critical for companies in the biopharmaceutical space to understand its foundational role when navigating freedom-to-operate strategies involving anti-CD4 antibodies.
FAQs
1. How did U.S. Patent 4,879,277 influence subsequent biologic drug patents?
It laid the groundwork for humanized monoclonal antibody patents, influencing both patent law and scientific innovation. Its broad claims have been cited in numerous subsequent patents relating to antibody engineering, therapeutic applications, and diagnostics.
2. Are the claims of U.S. 4,879,277 still enforceable today?
No. The patent expired in 2006, rendering its claims unenforceable. However, its scientific disclosures serve as prior art and influence newer patents and innovations.
3. Does this patent cover all anti-CD4 antibodies?
No. It covers specific humanized monoclonal antibodies with defined sequences and characteristics. Variations outside these parameters are not protected under this patent.
4. What are the key patent landscapes for anti-CD4 monoclonal antibodies?
They include early hybridoma patents, later glycoengineering and conjugation patents, and newer biosimilar patents. The landscape supports ongoing innovation but also poses freedom-to-operate challenges.
5. How does the patent landscape affect biosimilar development?
Once patents like 4,879,277 expire, biosimilar manufacturers can develop similar products. However, newer patents on specific antibody modifications, conjugates, or formulations may still constrain certain claims.
References
[1] U.S. Patent No. 4,879,277, "Humanized Monoclonal Antibody to Human CD4," issued November 7, 1989.
[2] Trends and patent filings via USPTO database, 1980-2023.
[3] Relevant literature on antibody engineering and biologics patents cited in footnotes.
More… ↓
⤷ Start Trial
|
